CoMentis Company
AmCyte develops encapsulated proliferated human islets for transplantation into patients with diabetes. The company specializes in adult stem cell research to treat diabetes with islet replacement therapy.
Investors
Founded Date:
2004
Total Funding:
$107.5M
Investor Type:
N/A
Employee Number:
51-100
Investment Stage:
N/A
Funding Status:
Late Stage Venture
Number Of Exists:
N/A
Technology:
Stem Cell
Last Funding Type:
Series E
Investors Number:
14
Industry:
Regenerative medicine
Headquarters:
United States